AGMB - AgomAb Therapeutics N.V. American Depositary Shares News

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phas

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Diseas

-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mond

Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what a

HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Targe

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NA

AgomAb Therapeutics: High Risk, High Reward Stock

AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drug

Agomab Announces Results of Annual General Meeting

Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage

Agomab to Participate in Upcoming Conferences

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

-- Cash and Cash Investments at December 31, 2025 of €116. 5 Million and Gross Proceeds of $208 Mill

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of AL

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“'Agomab'”), a clinical-st

defenseworld.net

Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep

defenseworld.net

Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations Fo

Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change

Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday

Agomab Announces Closing of Initial Public Offering

ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab

U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are

reuters.com

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-bas

Agomab Announces Pricing of Initial Public Offering

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January